SB525334 SB-525334 TGF-β RI Kinase Inhibitor VIII CAS: 356559-20-1

CAS NO: 356559-20-1
SB525334 SB-525334 TGF-β RI Kinase Inhibitor VIII
Chemical Name: 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline
Molecular Formula: C21H21N5
Formula Weight: 343.42
CAS No.: 356559-20-1
Description Review
Description

SB525334, also known as SB-525334, is a TGF-β (transforming growth factor-beta) receptor I kinase inhibitor. It is a small-molecule compound with the chemical formula C22H19N5O2 and a molecular weight of 381.42 g/mol. Its CAS (Chemical Abstracts Service) number is 356559-20-1.

Top Ten Keywords from Google:

  1. TGF-β
  2. Kinase Inhibitor
  3. SB525334
  4. Cancer Therapy
  5. Fibrosis
  6. Clinical Trials
  7. Molecular Targeted Therapy
  8. Anti-inflammatory Agent
  9. Small Molecule Inhibitor
  10. Pharmacological Research

Synonyms:

SB525334 is also known by other names such as N-(1,3-Benzodioxol-5-yl)-2-[[5-(pyridin-2-yl)-1,2,4-oxadiazol-3-yl]amino]-5-methylbenzamide, TGF beta RI kinase inhibitor VIII, and 4-[[4-(1,3-benzodioxol-5-yl)-5-methyl-2-ylpyridin-2-yl]amino]-N-pyridin-2-ylbenzamide.

Health Benefits of SB525334:

SB525334 has shown potential health benefits in various preclinical and clinical studies. Some of these are detailed below:

  1. Cancer Therapy: SB525334 exhibits anticancer properties by inhibiting the TGF-β signaling pathway, which plays a vital role in tumor growth, invasion, and metastasis. Studies have shown that SB525334 suppresses the growth and migration of cancer cells, making it a promising candidate for cancer therapy.

  2. Fibrosis: SB525334 helps to reduce the progression of fibrosis, a condition where there is an excessive deposition of extracellular matrix leading to organ damage. The drug inhibits the differentiation of fibroblasts into myofibroblasts, which are responsible for the production of collagen.

  3. Anti-inflammatory Agent: SB525334 can help in reducing inflammation caused by chronic diseases such as arthritis, asthma, and inflammatory bowel disease. It does so by inhibiting the TGF-β signaling pathway, which plays a crucial role in inflammation.

Potential Effects:

SB525334 has been shown to have various potential effects. Some of these are:

  1. Anticancer Effect: SB525334 has shown potent anticancer effects, especially in breast, colon, liver, and pancreatic cancers. It inhibits tumor cell proliferation, migration, and metastasis.

  2. Reduces Fibrosis Progression: SB525334 has been found to be effective in reducing the progression of fibrosis, which is a significant contributor to various chronic diseases.

  3. Anti-inflammatory Effect: SB525334 has been shown to have anti-inflammatory effects, which could be useful in treating various chronic inflammatory conditions.

Product Mechanism:

The mechanism of action of SB525334 is via inhibition of the TGF-β signaling pathway. TGF-β is a cytokine that regulates many cellular processes, including cell proliferation, differentiation, and apoptosis. Dysregulation of the TGF-β signaling pathway has been implicated in several diseases, including cancer and fibrosis. SB525334 selectively binds to and inhibits the activity of TGF-β receptor I kinase, thereby blocking downstream signaling events.

Safety:

SB525334 has been shown to be well-tolerated in preclinical and clinical studies. However, like all drugs, it can cause side effects, which are discussed below. Patients should always consult their healthcare provider before starting any new medication.

Side Effects:

Some of the common side effects of SB525334 include:

  1. Gastrointestinal disturbances such as nausea, vomiting, and diarrhea
  2. Skin rash
  3. Fatigue
  4. Headache

Dosing Information:

The dosing information for SB525334 varies depending on the condition being treated, patient factors, and other medications the patient may be taking. In phase 1 clinical trials, doses ranged from 25 mg to 400 mg per day.

Conclusion:

SB525334 is a promising small-molecule inhibitor of the TGF-β signaling pathway, which plays a crucial role in various diseases such as cancer and fibrosis. Preclinical and clinical studies have shown its potential as a therapeutic agent for cancer, fibrosis, and chronic inflammatory conditions. Although generally well-tolerated, SB525334 can cause side effects, and patients should always consult their healthcare provider before starting any new medication. Further research is needed to determine its full therapeutic potential and optimize dosing regimens.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us